Navigation Links
Trius Awarded $28 Million Contract to Develop Novel Antibiotics
Date:10/21/2008

Funding from NIAID of National Institutes of Health

SAN DIEGO, Oct. 22 /PRNewswire/ -- Trius Therapeutics, Inc., today announced the award of a $28 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, for the development of novel antibiotics directed against multiple Gram-negative bacterial pathogens. Under the five-year contract, Trius will develop novel drugs targeting bacterial DNA Gyrase and Topoisomerase IV, with the aim of optimizing these drugs for activity against relevant biodefense pathogens such as Yersinia pestis, Francisella tularensis, and Burkholderia pseudomallei. Trius will collaborate with investigators at Lawrence Livermore National Laboratories to identify and optimize lead molecules and to test these compounds for activity against Gram-negative biodefense pathogens.

"We will focus our efforts to address the NIAID mission to develop new medical countermeasures against biological agents most likely to be used in a terror attack on civilian populations," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "Trius offers a novel approach to develop effective new drugs to treat infections caused by such deadly pathogens."

"Our structure based drug design approach has already identified a number of promising lead molecules," said John Finn, Ph.D., Principal Investigator of the NIAID contract and Chief Scientific Officer of Trius. "Under this contract, we will optimize these compounds for activity against a wide spectrum of key Gram-negative biodefense pathogens, and along the way, we will likely discover compounds active against bacteria responsible for more common hospital infections for which there are few current treatment options."

Federal funding will be provided for this project by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services. The project will be 100% federally funded in the amount of $27,677,143.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, TR-701, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R). Trius has licensed worldwide rights outside of Korea to TR-701 from Dong-A Pharmaceuticals. Trius' pipeline includes two preclinical programs being developed to treat serious infections including those caused by Gram-negative bacterial pathogens. For more information, visit http://www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trius Appoints Paul Truex to Board of Directors
2. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
3. Mirus Bio Awarded Grants & Contracts of Over $5 Million
4. ICx Awarded $1.5 M Contract by Department of Homeland Security for Development of Next Generation Bio Aerosol Systems
5. ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS
6. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
7. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
8. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
9. Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics
10. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
11. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
Breaking Biology Technology:
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/9/2016)... in attendance control systems is proud to announce the introduction of fingerprint attendance control ... right employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):